Continuation versus discontinuation of RAAS inhibitors in hospitalized patients with COVID-19
Evidence Based Medicine presented by InpharmD™ · InpharmD™
January 25, 20215m 34s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A prospective, randomized, open-label trial performed to evaluate whether continuation of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is beneficial or harmful in patients who are admitted to hospital with COVID-19.